Clinical Trials Logo

Chronic Lymphocytic Leukemia clinical trials

View clinical trials related to Chronic Lymphocytic Leukemia.

Filter by:

NCT ID: NCT03438344 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Start date: December 2018
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well multi-antigen cytomegalovirus (CMV)-modified vaccinia Ankara vaccine works in reducing CMV related complications in patients with blood cancer who are undergoing donor stem cell transplant. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill cancer cells.

NCT ID: NCT03370185 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

BRIO
Start date: February 12, 2018
Phase: Phase 2
Study type: Interventional

This is a multi-center, single-arm, open-label, Phase 2 study of duvelisib, an orally bioavailable dual inhibitor of PI3K-δ,γ, in patients with CLL/SLL who have previously been treated with ibrutinib or another Bruton's Tyrosine Kinase Inhibitor (BTKi) and relapsed or were refractory to such therapy or discontinued such therapy due to toxicity.

NCT ID: NCT02993536 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab

Start date: November 2015
Phase:
Study type: Observational

The purpose of the study is to assess the evolution of B cells at a genetic and surface-marker level in high-risk CLL after idelalisib-rituximab treatment. The targeted population includes 20 subjects ages 18 or older diagnosed with high-risk CLL. This will include patients with relapsed or refractory disease who require therapy with idelalisib and rituximab as per FDA label. This is an observational study for peripheral blood samples of these patients collected at pre-determined time points.

NCT ID: NCT02677948 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Start date: October 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This study combines two drugs in the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Investigators are proposing combining ibrutinib, an orally-administered, small molecule inhibitor of Bruton's tyrosine kinase (FDA approved for the treatment of relapsed/refractory CLL), with pacritinib, a novel JAK2-FLT3 inhibitor that has shown activity in relapsed lymphoma, including CLL/SLL. Investigators will first demonstrate the safety and tolerability of Pacritinib when combined with Ibrutinib in a phase I study, which will help establish the MTD (Maximum Tolerated Dose)of Pacritinib when combined with Ibrutinib. Once the optimal dose of Pacritinib is established in the phase I setting, a phase II evaluation will seek to establish the efficacy of the combination of Pacritinib with Ibrutinib. Patients will receive continuous treatment until progressive disease and will be followed while on study treatment for a total of 2 years.

NCT ID: NCT02640833 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

Start date: July 2016
Phase: Phase 1
Study type: Interventional

This study is designed to assess the safety, pharmacokinetics, drug-drug interactions, and determine the recommended Phase 2 doses of co administered Duvelisib and Venetoclax in participants with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, or indolent or aggressive non-Hodgkin lymphoma, who have not previously received a Bcl-2 or Phosphoinositide 3-kinase (PI3K) inhibitor. The Phase 2 portion of the study will preliminarily evaluate efficacy, and expand the toxicity evaluation.

NCT ID: NCT02611908 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.

Start date: June 2016
Phase: Phase 1
Study type: Interventional

The purpose of the study is to investigate whether the combination of obinutuzumab and ibrutinib (administered up to 840 mg per day) might be useful for the treatment of CLL or SLL that is not responding or no longer responding to treatment with ibrutinib alone. The study will evaluate whether this regimen can reduce the amount of cancerous cells in the body. Subjects will be treated with ibrutinib at a dose of up to 840 mg a day by mouth, as well as obinutuzumab infusions. Although both of these agents are approved by the FDA for the treatment of CLL or SLL, the combination and the dosing schedule of ibrutinib are considered experimental.

NCT ID: NCT02371590 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

Lenalidomide and Obinutuzumab for Previously Untreated CLL

Start date: February 2018
Phase: Phase 2
Study type: Interventional

This is phase 1/2 study for patients with CLL or (SLL) who have not been previously treated. This study will evaluate whether obinutuzumab and lenalidomide is safe and tolerable in this setting and induce complete clinical responses.

NCT ID: NCT01739491 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia

Start date: October 2014
Phase: Phase 4
Study type: Observational

The purpose of this study is to assess safety and effectiveness of extended bendamustine in the treatment of chronic lymphocytic leukemia (CLL).

NCT ID: NCT01659047 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia

Start date: August 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of GS-1101 on the onset, magnitude, and duration of tumor control

NCT ID: NCT01271283 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia

Start date: December 2010
Phase: Phase 2
Study type: Interventional

This phase II clinical trial is studying how well lenalidomide works in treating patients with high-risk chronic lymphocytic leukemia. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing.